Georgia is currently home to 1984 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Atlanta, Augusta, Decatur and Savannah. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Neurostimulation
NCT04950894
Recruiting
Multi-center, open-label, prospective, randomized clinical trial of the aura6000(R) System for the reduction of apnea and hypopneas in adult patients with moderate to severe obstructive sleep apnea who have failed or are unwilling to use positive airway pressure treatment.
Gender:
All
Ages:
22 years and above
Trial Updated:
02/02/2023
Locations: Advanced Ent Associates, Atlanta, Georgia
Conditions: Obstructive Sleep Apnea, OSA, Apnea, Apnea, Obstructive, Apnea, Obstructive Sleep, Apnea+Hypopnea, Hypopnea, Sleep
Register for Updates
The Influence of the Otago Exercise Program on Executive Function Among People Living With Mild to Moderate Dementia
NCT05488951
Recruiting
The primary aim of this study is to conduct a pilot 6-month assessor-blinded randomized controlled trial to determine if the Otago Exercise Program plus usual care improves executive function in people living with mild to moderate dementia compared to usual care among those living in a nursing home or assisted living facility. The exploratory aims are to determine if the Otago Exercise Program plus usual care improves inflammatory blood biomarkers, kynurenine metabolites, epigenetics, mobility,... Read More
Gender:
All
Ages:
55 years and above
Trial Updated:
01/30/2023
Locations: Augusta University, Augusta, Georgia
Conditions: Dementia
Register for Updates
A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors
NCT05453825
Recruiting
This is a study of navicixizumab monotherapy or in combination with paclitaxel or irinotecan in patients with advanced cancer. Patients will be enrolled into one of the following cancer cohorts: Cohort A: CRC Cohort B: Gastric and GEJ cancer Cohort C: TNBC Cohort D: Platinum-resistant/refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer (ovarian cancer)
Gender:
All
Ages:
18 years and above
Trial Updated:
01/30/2023
Locations: Northside Hospital, Atlanta, Georgia
Conditions: Colorectal Cancer, Triple Negative Breast Cancer, Gastric Cancer, Ovarian Cancer
Register for Updates
Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC
NCT05199818
Recruiting
The phase 3 study is to compare the efficacy and safety of palonosetron, a long-acting 5-HT3 receptor antagonist, by buccal film delivery compared to IV injection for the prevention of chemotherapy-induced nausea and vomiting. Subjects receive a single dose of palonosetron prior to moderately emetogenic chemotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/19/2023
Locations: Summit Cancer Care, Savannah, Georgia
Conditions: Chemotherapy-induced Nausea and Vomiting
Register for Updates
AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Boys With DMD
NCT05683379
Recruiting
This is an observational screening study to evaluate the prevalence of anti-adeno-associated serotype 8 (AAV8) antibodies in participants with Duchenne muscular dystrophy (DMD).
Gender:
Male
Ages:
Between 0 years and 11 years
Trial Updated:
01/12/2023
Locations: Rare Disease Research, Atlanta, Georgia
Conditions: Duchenne Muscular Dystrophy
Register for Updates
Closed Loop Glucose Control in Patients With Type 1 and Type 2 Diabetes
NCT05644730
Recruiting
This is a proof of concept safety study of an artificial intelligence based closed loop glucose control system designed for use in the intensive care unit setting. The type 1 and type 2 diabetic subjects in this study will have their glucose controlled to a range of 100-140 mg/dL by a novel artificial intelligence based closed loop glucose control system for a period of 24 hours. The subjects will consume three standardized meals during the 24 hour study period.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
12/31/2022
Locations: Emory University, Atlanta, Georgia
Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Register for Updates
Identification of Patients With a High Probability of Meeting Eligibility Criteria for an Alzheimer's Disease Clinical Trial (APHELEIA)
NCT05364307
Recruiting
Apheleia-001 is a prescreener that aims to identify and characterize participants with reported cognitive impairment using demographic information, clinical history, brief cognitive assessments, and blood-based biomarkers to distinguish appropriate participants for referral to a therapeutic AD clinical trial.
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
12/28/2022
Locations: iResearch, Decatur, Georgia
Conditions: Alzheimer Disease, Mild Cognitive Impairment, Memory Loss, Memory Disorders, Memory Impairment
Register for Updates
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
NCT04883437
Recruiting
This phase II trial studies the effect of acalabrutinib and obinutuzumab in treating patients with follicular lymphoma or other indolent non-Hodgkin lymphoma for which the patient has not received treatment in the past (previously untreated). Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with obinutuzumab may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread. Givin... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/15/2022
Locations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Conditions: Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Indolent Non-Hodgkin Lymphoma, Lymphoplasmacytic Lymphoma, Lymphoproliferative Disorder, Mantle Cell Lymphoma, Marginal Zone Lymphoma
Register for Updates
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
NCT03817502
Recruiting
The purpose of this study is to evaluate the efficacy and safety of cariprazine in the treatment of schizophrenia in the adolescent population.
Gender:
All
Ages:
Between 13 years and 17 years
Trial Updated:
12/15/2022
Locations: Atlanta Center for Medical Research, Atlanta, Georgia
Conditions: Schizophrenia
Register for Updates
Assessing the Tendons With Shear Wave Elastography
NCT03456778
Recruiting
The purpose of this prospective study is to utilize a real-time ultrasound modality known as real-time Shear Wave Elastography (SWE) to first study the viscoelastic properties of tendons, such as the Achilles, patellar, quadriceps, epicondylar, and rotator cuff, to understand the functional differences between normal/asymptomatic vs tendinotic/symptomatic tendon states. The secondary aim will be to assess the degree of tendon healing after percutaneous tenotomy (a minimally invasive technique th... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
12/15/2022
Locations: Emory Orthopaedics and Spine Center, Atlanta, Georgia
Conditions: Achilles Tendinopathy, Tendinopathy
Register for Updates
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT02817633
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy
Gender:
All
Ages:
18 years and above
Trial Updated:
12/09/2022
Locations: GSK Investigational Site, Atlanta, Georgia
Conditions: Neoplasms
Register for Updates
Evaluate F901318 Treatment of Invasive Fungal Infections in Patients Lacking Treatment Options
NCT03583164
Recruiting
A study to evaluate F901318 (study drug) for the treatment of invasive fungal infections in patients lacking suitable alternative treatment options.
Gender:
All
Ages:
16 years and above
Trial Updated:
11/30/2022
Locations: Emory University, Atlanta, Georgia
Conditions: Invasive Fungal Infections
Register for Updates